Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157 ORAL Beverly Hills Rejuvenation Center Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy